01-11-2020 | Disease Modifying Anti-Rheumatic Drug | Review Article
Managing rheumatoid arthritis during COVID-19
Published in: Clinical Rheumatology | Issue 11/2020
Login to get accessAbstract
Key Points • Patients on immunosuppressive medications are not found to be at a greatly increased risk of acquiring COVID-19 infection. • Patients doing well on a stable dose of steroid and/or Disease-Modifying Antirheumatic Drugs (DMARDs) should be allowed to continue the same unless they get infected in which case, temporary stoppage of methotrexate and leflunomide may be considered. • Initiation of high-dose steroids, DMARDs, and biologics, if the clinical situation demands so, can be done. • Maintenance biologic therapy for stable patients should be individualized by the treating physician. |